Arrowhead Pharmaceuticals (ARWR) Other Non-Current Assets (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Other Non-Current Assets came in at $4.9 million in Q1 2026, up 272.48% YoY from $1.3 million in Q1 2025, and up 246.35% on a QoQ basis from $1.4 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Other Non-Current Assets data on file, last reported at $4.9 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 272.48% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 272.48% YoY) and the FY2025 annual result came in at $1.4 million, down 69.01% from the prior year.
- Other Non-Current Assets grew to $4.9 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $4.9 million in Q1 2026 to a low of $210000.0 in Q4 2022.
- A 5-year average of $1.6 million and a median of $1.3 million in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets jumped 2023.81% — and 2025, when it plunged 69.66%.
- Tracing ARWR's Other Non-Current Assets over 5 years: stood at $210000.0 in 2022, then gained by 10.48% to $232000.0 in 2023, then soared by 1228.88% to $3.1 million in 2024, then sank by 54.23% to $1.4 million in 2025, then jumped by 246.35% to $4.9 million in 2026.
- The last three Other Non-Current Assets figures came in at $4.9 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | 6.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.05 Mn |
| Mar 31, 2026 | 4.89 Mn |
| Dec 31, 2025 | 1.41 Mn |
| Sep 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Sep 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 4.46 Mn |
| Mar 31, 2024 | 210,000.00 |
| Dec 31, 2023 | 232,000.00 |
| Sep 30, 2023 | 3.26 Mn |
| Jun 30, 2023 | 210,000.00 |
| Mar 31, 2023 | 210,000.00 |
| Dec 31, 2022 | 210,000.00 |
| Sep 30, 2022 | 218,000.00 |
| Jun 30, 2022 | 275,000.00 |
| Mar 31, 2022 | 275,000.00 |
| Dec 31, 2021 | 273,000.00 |
| Sep 30, 2021 | 272,000.00 |